PDS Biotechnology is a clinical-stage immunotherapy company developing a pipeline of molecularly targeted immunotherapies designed to overcome the limitations of existing immunotherapy and vaccine technologies. Co. owns the proprietary T-cell activating platforms designed to train the immune system to attack and destroy disease; Versamune®, for treatments in oncology and Infectimune, for treatments in infectious disease. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies. Co. is developing targeted product candidates to treat cancers including Human Papillomavirus associated cancers, melanoma, colorectal, lung, breast and prostate cancers. The PDSB stock yearly return is shown above.
The yearly return on the PDSB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PDSB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|